Among the targets in our chemical probe collection, several have agents currently in clinical trials for cancer (EZH2, EED, DOT1L, PRMT1, and PRMT5) and additional PMT inhibitors are in preclinical studies. This evidence concerns the gene DOT1L and cancer.